22 results about "During menopause" patented technology

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

The present invention relates to an oral extract composition comprising Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) extract composition, and its process of preparation. Also relates to the oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient for, improvement, and maintenance of women health more preferably in improving of hot flashes, night sweats, poor sleep, anxiety, sexual dysfunction, mood changes, Genitourinary symptoms in overall improving the quality of life, serum estradiol, progesterone, follicle stimulating hormone (FSH), and cortisol during the period of menopause (perimenopause and menopause). The oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient is used for improving Brain-derived neurotrophic factor (BDNF) levels in women during the period of menopause. The present invention, further related to the extraction process of Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.), also provides the process for the preparation of formulation composition. This invention further relates to the extraction process from Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) either as individual herbs or co-extraction of the two herbs or mixing the extracts at various stages of the individual extracts.

The invention relates to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating perimenopausal syndrome, which is composed of podophyllum hexandrum, lagotis, honeysuckle fruit, bamboo shavings, pilose antler and sea-buckthorn. The composition takes podophyllum hexandrum as a monarch drug, sea-buckthorn and honeysuckle fruit as ministerial drugs to enhance the effects of promoting blood circulation and regulating menstruation, cornu cervi pantotrichum for replenishing essence and blood, warming yang and dispelling cold, and bamboo shavings and lagotis herb as adjuvant drugs for cooling blood and clearing heat, so that a three-dimensional system of promoting blood circulation, tonifying and clearing heat is formed. It is verified that the composition can relieve uterine atrophy, improve organic decline of a reproductive system, reduce whole blood viscosity and abnormally-increased leukocyte number, inhibit inflammation, accurately adjust serum E2, LH, PROG and AMH levels so as to remodel hormone balance and avoid side effects of exogenous hormones. The composition is based on the advantages of Tibetan medicines and the multi-target effect of natural medicinal materials, conforms to the modern research and development trend and is high in clinical transformation value.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating perimenopausal syndrome. The invention provides application of a Dan'e Fukang preparation in preparation of a medicine for treating perimenopausal syndrome. Pharmacological experiments prove that Dan'e Fukang can reduce the number of activities of mice and prolong the sleep time of the barbital sodium of the mice, and has certain sedative, hypnotic and anxiety-resistant effects; the composition can effectively resist rat foot plantar sweat secretion caused by pilocarpine, and has a certain effect of resisting sweating; moreover, the traditional Chinese medicine composition has an obvious effect of reducing LH, FSH and T in climacteric rats, has an effect of increasing E2 in serum of the climacteric rats, and can be used for effectively treating the perimenopausal syndrome. Dan'e'fukang can reduce the total accumulated immobility time of the rat in the forced swimming experiment; the despair state time of a tail suspension experiment rat is obviously shortened, and a certain anti-depression effect is achieved. The Dan'e Fukang can provide more drug choices for clinical treatment of perimenopausal syndrome diseases.

Embodiments of the invention comprise a test strip configured to detect one or more metabolites of progesterone in urine, and optionally further detect one or more additional metabolites or hormones in urine within the same test strip. Embodiments of the invention are methods of utilizing such a test strip in association with avoidance of pregnancy, detection of menopause, and in association with fertility planning purposes. Embodiments of the invention are associated with the incorporation of a test strip within a testing kit, optionally further comprising a digital reader.

The invention discloses a composition for regulating female endocrine and a preparation method thereof. Belongs to the technical field of biological medicine. The invention aims to solve the defects of female endocrine dyscrasia in the prior art, including unstable curative effect, slow effect, inconvenience in taking and the like, through the synergistic effect of specific components and an optimized preparation process. According to the composition, a prepared rehmannia root extract, a coptis chinensis extract, a white peony root extract, a scutellaria baicalensis extract, donkey-hide gelatin and poria cocos are taken as main active ingredients, oryzanol, vitamin B6 and 7-methylisonorethindrone are taken as auxiliary ingredients, and comprehensive regulation on female endocrine systems with climacteric and menopausal syndromes is realized through a scientific proportion and a unique preparation process. The components in the traditional Chinese medicine composition have a synergistic effect and comprehensively and accurately regulate endocrine, the core traditional Chinese medicine extracts are complementary, the endocrine dyscrasia mechanism is improved in a targeted manner, and the curative effect stability is guaranteed through scientific proportioning; the extraction process is optimized, and the utilization rate and activity of effective components are improved; the product form and the taking mode are optimized, the user compliance is improved, the multi-scene requirement is met, and the industrial pain point is solved.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including in overweight or obese subjects. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation or symptoms of menopause, including in overweight or obese subjects.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize alcohol-soluble species, including nonderivatized hormones. More preferably, the modified oil phase droplets of the MOIW microemulsion directly solubilize nonderivatized hormones. The oil phase droplets of the MOIW microemulsion include DHEA, pregnenolone, and a polyphenol, where a ratio of DHEA to polyphenol is from 1:1 to 12:1 by weight. Methods of supporting and / or increasing bloodstream hormone levels in perimenopausal and postmenopausal females and improving menopausal symptoms also are disclosed.

Methods and compositions increase iron absorption, for example by increasing iron absorbability and / or increasing iron bioavailability. A method for increasing iron absorption, preferably naturally present in plant-based food, meal or diet, includes administering to an individual in need thereof a milk-based composition galactooligosaccharide (GOS), preferably a low sugar low lactose milk composition comprising galactooligosaccharide (GOS). The individual, to whom the milk-based composition is administered, may be chosen from adults; older adults; pregnant or lactating women; menopausal or perimenopausal women, infants; children; and subjects consuming a vegetarian diet, a flexitarian diet, a vegan diet or any type of plant-based diet.

The application discloses application of a liver 20-HETE synthesis inhibitor in preparation of a medicine for treating perimenstrual mood disorders. The application constructs a perimenstrual mouse model through ovariectomy, and it is observed through behavior test that the perimenstrual model mouse shows obvious depressive and anxious behaviors. The expression of 20-HETE synthesis enzyme Cyp4a12a in the liver of the ovariectomy model mouse is significantly increased, and the 20-HETE level in the plasma is significantly increased. Through intervention by using a liver 20-HETE synthesis enzyme inhibitor TS-011, the 20-HETE content in the plasma of the ovariectomy mouse is significantly reduced, and the depressive and anxious behaviors of the mouse are obviously improved. It is found by the application that the liver 20-HETE synthesis inhibitor can be applied to development or preparation of a perimenstrual mood disorder treatment medicine with low side effects and high clinical acceptance, and has high clinical transformation value.

The application relates to a traditional Chinese medicine composition for nourishing kidney and relieving depression as well as a preparation method and application thereof. The application relates to a traditional Chinese medicine composition and a preparation method and application thereof. In order to solve the problems that long-term hormone replacement therapy not only has more adverse reactions, but also has potential risks of causing endometrial lesions, thrombosis and tumors, the traditional Chinese medicine composition comprises radix codonopsis, radix ophiopogonis, taxilli herba, radix dioscoreae, ligustri fructus, anemarrhena asphodeloides, herba ecliptae, radix paeoniae alba, radix bupleuri, pericarpium citri reticulatae, fritillaria, poria cocos, semen ziziphi spinosae and schisandra chinensis. The traditional Chinese medicine composition is applied to preparation of a medicine for preventing and / or treating perimenopausal syndrome and premature ovarian failure. The application belongs to the technical field of medicines.

The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component.The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.

The disclosure provides methods of reducing or eliminating the need for ovarian function suppression (OFS) in a premenopausal or perimenopausal female patient with hormone receptor-positive (HR+) breast cancer. The method comprises the administration of an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or a functional derivative thereof in neoadjuvant and adjuvant treatment.

The invention provides application of oviductus ranae in preparation of drugs for preventing and / or treating perimenopausal depression, and particularly belongs to the technical field of drugs for perimenopausal depression. The invention provides application of oviductus ranae in preparation of a medicine for preventing and / or treating perimenopausal depression. The oviductus ranae can remarkably improve depression-like behaviors of mice with perimenopausal depression and has the effect of treating the perimenopausal depression. Specifically, the oviductus ranae can increase sucrose intake of mice with perimenopausal depression, improve social behaviors, increase exploration desire, repair neuron damage, reduce the levels of FSH, LH and CORT in serum, up-regulate the content of 5-HT and 5-HIAA neurotransmitters and improve the expression level of brain neurotrophic factors BDNF and estrogen receptor ERalpha and ERbeta proteins, and has the effect of regulating and controlling PI3K / AKT signal channels.

The disclosure provides methods of reducing or eliminating the need for ovarian function suppression (OFS) in a premenopausal or perimenopausal female patient with hormone receptor-positive (HR+) breast cancer. The method comprises the administration of an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or a functional derivative thereof in neoadjuvant and adjuvant treatment.

The present application discloses Lactobacillus reuteri and its application in relieving perimenstrual syndrome, and relates to the technical field of biology. Limosilactobacillus reuteri ​ Lactobacillus reuteri (Lactobacillus reuteri) -NCU-37 was preserved in China General Microbiological Culture Collection Center on February 24, 2025, and the address is No. 1, Xibaixili, Chaoyang District, Beijing, and the preservation number is CGMCC NO. 33627. The Lactobacillus reuteri -NCU-37 of the present application can relieve perimenstrual syndrome induced by leuprolide in assisted reproductive treatment, specifically relieve perimenstrual syndrome and related emotional disorders (including anxiety, depression and insomnia), improve the hormone level of infertile women with perimenstrual syndrome, and relieve the symptoms of infertile women with perimenstrual syndrome by regulating intestinal flora diversity.

The application discloses a novel vaccine suitable for lipid-lowering and blood sugar-lowering castration of multiple species, a preparation method and application thereof, and is related to one or more combinations of a YETVKVPGCAHHADSL fragment of pigs, cattle, sheep, alpacas and horses, a YETVRVPGCARHADSL fragment of dogs and minks, a YPVATECHCGK fragment of pigs, cattle, sheep, alpacas, cats, rabbits and mice, a CDSDSTDCTVRGLGP fragment of humans, pigs, cattle, sheep, alpacas, dogs, giant pandas, rabbits and mice, and a CDSDSTDCTVQGLGP fragment of cats, tigers and lions, and a sequence with a homology of more than 70% to any one of the fragments. The protein vaccine can be effectively applied to treat diseases such as obesity, hyperlipidemia and diabetes caused by ovarian dysfunction, has pet and animal sterilization effects, can treat postmenopausal women or animals and pets that have undergone sterilization or castration surgery, and diseases such as obesity, hyperlipidemia and hyperglycemia caused by ovarian dysfunction, and has a good popularization prospect and medical economic value.

This invention belongs to the field of pharmaceutical technology, specifically relating to a composition for improving perimenopausal symptoms. It comprises the following components: 400-700 parts protein, 30-50 parts fat, 120-170 parts carbohydrates, 40-90 parts dietary fiber, 30-80 parts food-grade medicinal materials, 2-6 parts complex trace minerals, 50-95 parts complex macrominerals, 3-5 parts complex vitamins, and 5-10 parts blueberry powder. The protein is composed of whey protein, soy protein, and collagen peptides in a mass ratio of 7-12:6.1-8.5:1. By precisely controlling the ratio of soy protein and collagen peptides in the protein, this composition can significantly improve perimenopausal symptoms such as hot flashes, insomnia, osteoporosis, decreased estrogen levels, and uterine atrophy.

The present invention relates to the field of Premenstrual dysphoric disorder (PMDD) and perimenopausal depression (PMD). More specifically, the present invention relates to the use of biomarkers to diagnose PMDD, PMD or predict a risk thereof. In one embodiment, a method for identifying a likelihood of PMDD and / or PMD in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring white blood cell type counts and DNA methylation levels of a panel of biomarkers or using a proxy marker to estimate the ratio monocytesmon-monocytes in the sample collected from the patient, wherein the panel of biomarkers comprises HP1BP3 and TTC9B and the white blood cell type counts comprise monocytes and non-monocytes; and (c) using a linear model that utilizes the DNA methylation level of HP1BP3 and TTC9B and the ratio of monocytesmon-monocytes or proxy marker to determine the patient is likely to develop PMDD and / or PMD.

The invention relates to the field of biomedical materials, and discloses a swine-derived acellular matrix material for treating menopausal genitourinary syndrome as well as a preparation method and a preparation of the swine-derived acellular matrix material. The method comprises the following steps: carrying out virus inactivation on swine-derived tissues, carrying out an antigen removal process combining pancreatin pretreatment and high-salt SDS and high-alkali SDS step-by-step treatment, and carrying out normal saline middle-pass cleaning, degreasing, last-pass cleaning, drying sterilization and the like to obtain the material. The method can deeply remove antigen substances such as DNA (deoxyribonucleic acid) and the like, reduce SDS (sodium dodecyl sulfate) and organic solvent residues and effectively retain a natural collagen structure and bioactive components at the same time. The DNA residual quantity of the obtained material is less than 50 ng / mg, the SDS residual quantity is less than 0.02%, and the fat content is less than 0.5%; bacterial endotoxin is less than 0.5 EU / mg, total sugar is greater than 0.2 mg / g, and total protein content is greater than 85%. The material can be prepared into particles or microspheres, is used for preparing preparations for treating symptoms such as vaginal mucosa atrophy, dryness and elasticity decline related to menopausal genitourinary syndrome, and has the functions of immediate support and long-term regeneration and repair.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize alcohol-soluble species, including nonderivatized hormones. More preferably, the modified oil phase droplets of the MOIW microemulsion directly solubilize nonderivatized hormones. The oil phase droplets of the MOIW microemulsion include DHEA, pregnenolone, and a polyphenol, where a ratio of DHEA to polyphenol is from 1:1 to 12:1 by weight. Methods of supporting and / or increasing bloodstream hormone levels in perimenopausal and postmenopausal females and improving menopausal symptoms also are disclosed.